Eun Yang
Stock Analyst at Jefferies
(0.53)
# 4,175
Out of 5,115 analysts
37
Total ratings
35%
Success rate
-24.48%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GBIO Generation Bio Co. | Downgrades: Hold | $11 → $5 | $5.63 | -11.11% | 1 | Dec 16, 2025 | |
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $44.64 | -5.91% | 1 | Nov 5, 2025 | |
| ATXS Astria Therapeutics | Downgrades: Hold | $30 → $13 | $13.01 | -0.08% | 3 | Oct 14, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $514.64 | -16.06% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $5.91 | +35.36% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.72 | +108.33% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $76.53 | -56.88% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.29 | +2,070.54% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $16.72 | +61.48% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.22 | +215.32% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.31 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.57 | +600.28% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $3.34 | +449,001.80% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.11 | +2,152.25% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $25.68 | +36.29% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $333.96 | -34.12% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $176.33 | +75.81% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $125.67 | -36.34% | 3 | Jul 11, 2017 |
Generation Bio Co.
Dec 16, 2025
Downgrades: Hold
Price Target: $11 → $5
Current: $5.63
Upside: -11.11%
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $44.64
Upside: -5.91%
Astria Therapeutics
Oct 14, 2025
Downgrades: Hold
Price Target: $30 → $13
Current: $13.01
Upside: -0.08%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $514.64
Upside: -16.06%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $5.91
Upside: +35.36%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.72
Upside: +108.33%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $76.53
Upside: -56.88%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.29
Upside: +2,070.54%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $16.72
Upside: +61.48%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.22
Upside: +215.32%
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $4.31
Upside: -
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.57
Upside: +600.28%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $3.34
Upside: +449,001.80%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.11
Upside: +2,152.25%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $25.68
Upside: +36.29%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $333.96
Upside: -34.12%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $176.33
Upside: +75.81%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $125.67
Upside: -36.34%